Why it can take time and effort to find the right meds to help mental health

The Long, Uncertain Road to Finding the Right Psychiatric Medication

Goldlaner.com – For millions of Americans living with depression, anxiety, or other psychiatric conditions, the search for a medication that actually works can feel like navigating a maze with no visible exit. Weeks may pass before a prescribed drug begins to take effect. Switching from one agent to another demands careful medical oversight. And the consequences of getting it wrong — or of being placed on too many agents simultaneously — can be devastating. The recent murder trial of Lindsay Clancy, a 36-year-old labor and delivery nurse who killed her three children in 2023, has thrust these questions into sharp public focus.

A Trial That Laid Bare the Risks of Polypharmacy

Clancy strangled her three young children, then slashed her own wrists and throat before jumping from a second-story window. The day before the killings, she typed a message on her phone: “medication stole my motherhood and my life.” Prosecutors briefly displayed that note to the jury during the trial. Mental health professionals who had treated her over the years took the stand and described how she repeatedly requested changes to dozens of prescriptions covering depression, anxiety, and other conditions.

In closing arguments, Clancy’s attorney Kevin Riddington argued that his client had been overmedicated and was not criminally responsible for the murders because she was experiencing a psychotic state. He pointed to a rare diagnosis called postpartum psychosis, a condition that, research indicates, carries an elevated risk of both infanticide and suicide when it goes untreated.

“She was reaching out for help, and she was not getting it,” Riddington told the court, as Clancy nodded from the defendant’s chair.

Prosecutor Jennifer Sprague offered a contrasting reading. She contended that the manner in which Clancy killed her children demonstrated premeditation, that Clancy understood the difference between right and wrong, that she had misled her mental health providers, and that she had failed to take her medications as directed.

“She knows, as a nurse, the importance of following the instructions of your medications,” Sprague told the jury.

Since the trial, Clancy has filed suit against her doctors. The lawsuit alleges they failed to diagnose her properly and instead “subjected her to a disorganized, uncoordinated course of polypharmacy that exacerbated her condition and precipitated a severe psychotic break.” All of the providers named in the case declined to comment while litigation is pending.

Dr. Joseph Goldberg, a psychiatrist and psychopharmacologist with no connection to the case, framed the trial’s broader significance:

“An opportunity to remind us all about the complexities of severe mental illness and the complexities of treating mental illness.”

The Scale of Psychiatric Medication Use in America

Medication remains the single most common treatment pathway for mental health conditions in the United States. The Centers for Disease Control and Prevention estimates that nearly 20 percent of American adults are currently taking at least one psychiatric drug. That figure encompasses everything from a single SSRI for seasonal depression to layered regimens for treatment-resistant schizophrenia. The sheer volume of prescriptions underscores why the question of “which drug, at what dose, for how long” is not a trivial one.

Psychiatric pharmacology generally organizes its agents into four or five major therapeutic categories. Each targets different neurotransmitter systems, carries its own side-effect profile, and operates on its own timeline. Understanding those distinctions helps patients and clinicians make informed decisions rather than defaulting to trial-and-error.

SSRIs: The Workhorse Class

Selective serotonin reuptake inhibitors — commonly called SSRIs — include brand names such as Celexa, Prozac, and Zoloft. They are prescribed across a spectrum of depressive and anxiety disorders and are regarded as highly effective first-line agents. Common early side effects include stomach upset, diminished libido, and headaches, though these tend to fade as the body adjusts.

The critical caveat is time. Because SSRIs alter how the brain processes serotonin — a neurotransmitter involved in mood regulation, sleep architecture, and appetite — they typically require four to eight weeks before a meaningful therapeutic effect emerges. An exception exists for menstrual-related mood disorders, where the hormonal milieu of the cycle can accelerate the onset of benefit.

At the cellular level, the mechanism is elegant. SSRIs block the rapid reuptake of serotonin back into presynaptic neurons. Serotonin therefore lingers longer in the synaptic cleft. Over days and weeks, postsynaptic receptors partially desensitize to the elevated signal. That downstream adaptation triggers the release of brain-derived neurotrophic factor, a protein that functions somewhat like fertilizer for neural tissue, encouraging the growth of new neurons and synapses. The cumulative effect is a gradual lifting of mood that no single dose can produce.

Other Antidepressant Mechanisms

Norepinephrine-dopamine reuptake inhibitors, or NDRIs, represent a different pharmacological strategy. Bupropion is the principal agent in this class. Rather than touching serotonin, it blocks the reabsorption of norepinephrine and dopamine — two neurotransmitters implicated in stress response, pleasure, reward processing, alertness, and sustained attention. Patients who experience SSRI-related sexual side effects sometimes find relief by switching to an NDRI, though the decision must be made with a prescriber.

Serotonin-norepinephrine reuptake inhibitors, or SNRIs, occupy a middle ground. Cymbalta, Fetzima, and Effexor XR inhibit the reuptake of both serotonin and norepinephrine simultaneously, thereby influencing the body’s fight-or-flight circuitry alongside mood regulation. They are often considered when an SSRI alone has not produced adequate relief.

Anti-Anxiety Agents: Fast Relief, Narrow Window

Benzodiazepines — Ativan, Librium, Xanax, and Valium among them — act rapidly to blunt extreme worry, fear, social anxiety, or acute panic attacks. Their speed is their greatest asset and also the reason clinicians prescribe them cautiously. Dependence develops with regular use, and the drugs can produce dangerous effects when central nervous system activity drops too far. For that reason, benzodiazepines are typically reserved for short-term bridging while a slower-acting antidepressant reaches therapeutic levels, or for episodic use under close supervision.

What the Clancy Case Reminds Patients

The trial does not settle a pharmacological question, but it does sharpen a practical one: how do patients advocate for themselves when a regimen is not working, when side effects accumulate, or when multiple prescribers are managing overlapping conditions? The answer, clinicians emphasize, is open communication with a treating psychiatrist or primary-care physician before making any change. Abruptly stopping or combining agents without medical guidance can destabilize a patient far more quickly than the original condition. In a field where the right molecule for one person is the wrong one for another, patience, documentation, and a trusted prescriber remain the most reliable safeguards.